The main objective of this study was to evaluate the efficacy of switching from omalizumab to dupilumab in severely asthmatic patients with an allergic phenotype, who are non-responsive to anti-IgE therapy, in terms of an exacerbation rate reduction, a decrease in OCS use, and improved lung function, as well as in those with uncontrolled asthma, despite optimized and maximal treatment. Here, IGHE is linked to asthma.